{"id":"torasemide","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":["Anuria","Ascites","Azotemia","Cirrhosis of liver","Dehydration","Gout","Hearing disorder","Hypertriglyceridemia","Hyperuricemia","Hypokalemia","Hypovolemia","Metabolic alkalosis"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"trials":[],"_chembl":{"chemblId":"CHEMBL1148","moleculeType":"Small molecule","molecularWeight":"348.43"},"aliases":["Demadex","Tortas","Wator","Torsemide"],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Torasemide","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:24:43.059726+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:24:49.593825+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Torasemide","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:24:49.928811+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Sodium-(potassium)-chloride cotransporter 2 inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:24:50.990214+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1148/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:24:50.642917+00:00"}},"offLabel":[],"timeline":[],"_dailymed":null,"ecosystem":[],"mechanism":{"target":"Solute carrier family 12 member 1"},"_scrapedAt":"2026-03-28T00:13:24.905Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:24:52.297374+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Decompensated cardiac failure","diseaseId":"decompensated-cardiac-failure","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Edema","diseaseId":"edema","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Edema due to Hepatic Cirrhosis","diseaseId":"edema-due-to-hepatic-cirrhosis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Hypertensive disorder","diseaseId":"hypertensive-disorder","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Peripheral Edema due to Chronic Heart Failure","diseaseId":"peripheral-edema-due-to-chronic-heart-failure","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Pulmonary Edema due to Chronic Heart Failure","diseaseId":"pulmonary-edema-due-to-chronic-heart-failure","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Renal Disease with Edema","diseaseId":"renal-disease-with-edema","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT06206512","phase":"PHASE2","title":"Effect of Extended Release Torsemide in Patients With Congestive Heart Failure and Overactive Bladder","status":"COMPLETED","sponsor":"Sarfez Pharmaceuticals, Inc.","startDate":"2024-06-15","conditions":"Heart Failure, Overactive Bladder, Incontinence","enrollment":24},{"nctId":"NCT06995144","phase":"PHASE4","title":"Comparing Natriuretic Effects of ER Torsemide to IR Torsemide in Patients With Heart Failure","status":"COMPLETED","sponsor":"Sarfez Pharmaceuticals, Inc.","startDate":"2025-05-28","conditions":"Heart Failure, Edema, Pulmonary Congestion","enrollment":20},{"nctId":"NCT07046975","phase":"PHASE3","title":"Bioavailability and Bioequivalence Study of Extended Release Torsemide and Spironolactone","status":"COMPLETED","sponsor":"Sarfez Pharmaceuticals, Inc.","startDate":"2025-06-15","conditions":"Bioavailability Heathy Volunteers","enrollment":24},{"nctId":"NCT07223502","phase":"PHASE3","title":"A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Disease","status":"RECRUITING","sponsor":"Sarfez Pharmaceuticals, Inc.","startDate":"2025-12-01","conditions":"Hypertension (HTN)","enrollment":30},{"nctId":"NCT07015671","phase":"PHASE3","title":"Bioavailability and Bioequivalence Study of ER Torsemide and Spironolactone FDC Tablet in Healthy Subjects","status":"COMPLETED","sponsor":"Sarfez Pharmaceuticals, Inc.","startDate":"2025-07-01","conditions":"Bioequivalence Study in Healthy Subjects, PK/PD","enrollment":24},{"nctId":"NCT07043634","phase":"PHASE3","title":"A Study to Evaluate the Effect of Food or no Food on the Bioavailability of an Extended Release (ER) Torsemide and Spironolactone Fixed Dose Combination (FDC) Tablet in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Sarfez Pharmaceuticals, Inc.","startDate":"2025-06-15","conditions":"Bioavailability Heathy Volunteers","enrollment":24},{"nctId":"NCT07201584","phase":"PHASE1","title":"A Comparative Bioavailability Study of Two Torasemide 10 mg Tablets Formulations in Healthy Adult Participants Under Fasting Conditions:","status":"RECRUITING","sponsor":"Berlin-Chemie AG Menarini Group","startDate":"2025-09-05","conditions":"Healthy Adult Male and Female Volunteers","enrollment":26},{"nctId":"NCT06036914","phase":"PHASE2","title":"A Study of Ultra High Dose Diuretics to Treat Heart Failure","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2023-11-27","conditions":"Heart Failure; With Decompensation","enrollment":20},{"nctId":"NCT07335900","phase":"NA","title":"A Clinical Study Using FAPI-PET Imaging to Assess the Postoperative Effects of TAVI in Patients With Aortic Stenosis","status":"RECRUITING","sponsor":"RenJi Hospital","startDate":"2025-12-19","conditions":"Severe Aortic Valve Stenosis","enrollment":25},{"nctId":"NCT05171686","phase":"PHASE4","title":"Diuretics and Volume Overload in Early CKD","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2023-02-01","conditions":"Chronic Kidney Disease, Hypertension","enrollment":49},{"nctId":"NCT03296813","phase":"PHASE3","title":"TRANSFORM-HF: ToRsemide compArisoN With furoSemide FORManagement of Heart Failure","status":"COMPLETED","sponsor":"Duke University","startDate":"2018-07-11","conditions":"Heart Failure","enrollment":2973},{"nctId":"NCT06670534","phase":"PHASE2","title":"A Dose-finding Study of JMKX003142 in Treatment of Renal Edema","status":"RECRUITING","sponsor":"Jemincare","startDate":"2025-01-07","conditions":"Edema Secondary, Edema Leg","enrollment":216},{"nctId":"NCT06292091","phase":"PHASE1","title":"A Study to Investigate the Effect of Urine Acid-base Disequilibrium on the Pharmacokinetics of Captopril","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2024-02-28","conditions":"Hypertension","enrollment":12},{"nctId":"NCT06708611","phase":"PHASE4","title":"A Crossover Study of Patients with HF to Compare Natriuretic Effects of IR Torsemide Vs. ER Torsemide Over 12 Hrs","status":"TERMINATED","sponsor":"Sarfez Pharmaceuticals, Inc.","startDate":"2025-01-15","conditions":"Heart Failure","enrollment":5},{"nctId":"NCT06176794","phase":"PHASE2","title":"Immediate Release Torsemide Versus Extended Release Torsemide After Salty Meal","status":"TERMINATED","sponsor":"Sarfez Pharmaceuticals, Inc.","startDate":"2024-11-15","conditions":"Heart Failure","enrollment":1},{"nctId":"NCT06362668","phase":"NA","title":"EU Sites: Fluid Management of Acute Decompensated Heart Failure With Reprieve Decongestion Management System (FASTR-EU)","status":"COMPLETED","sponsor":"Reprieve Cardiovascular, Inc","startDate":"2024-05-17","conditions":"Acute Decompensated Heart Failure","enrollment":12},{"nctId":"NCT05093621","phase":"PHASE3","title":"Torsemide Comparison With Furosemide for Management of Patients With Stable Heart Failure","status":"COMPLETED","sponsor":"Yale University","startDate":"2021-02-08","conditions":"Heart Failure","enrollment":47},{"nctId":"NCT06414759","phase":"PHASE4","title":"Efficacy and Safety of Combination Diuretic Therapy in Patients With Acute Decompensated Heart Failure and Volume Overload","status":"RECRUITING","sponsor":"Cairo University","startDate":"2024-07-01","conditions":"Acute Decompensated Heart Failure, Volume Overload, Edema","enrollment":110},{"nctId":"NCT06117722","phase":"","title":"TorasEmide Induced Effect on QoL and Clinical parameterS in paTients With chronIc heArt Failure Receiving Eplerenone.","status":"UNKNOWN","sponsor":"Elpen Pharmaceutical Co. Inc.","startDate":"2024-03-06","conditions":"Chronic Heart Failure","enrollment":210},{"nctId":"NCT06413082","phase":"PHASE3","title":"Pharmacogenetics of Torasemide and Spironolactone in Hypertension Treatment","status":"COMPLETED","sponsor":"Ospedale San Raffaele","startDate":"2021-02-15","conditions":"Hypertension, Genetic Predisposition, Drug Effect","enrollment":38},{"nctId":"NCT03509545","phase":"PHASE1","title":"Comparison of Once Daily 40 mg Torsemide With Twice-daily 40 mg Furosemide","status":"COMPLETED","sponsor":"Sarfez Pharmaceuticals, Inc.","startDate":"2021-06-30","conditions":"Body Weight Changes","enrollment":20},{"nctId":"NCT06275763","phase":"PHASE4","title":"Optimal Medical Treatment of Difficult-to-treat Hypertension","status":"UNKNOWN","sponsor":"National Institute of Cardiology, Warsaw, Poland","startDate":"2023-10-20","conditions":"Hypertension","enrollment":2500},{"nctId":"NCT06218199","phase":"PHASE4","title":"Diuretics vs. Afterload Reduction for Treatment of HeartLogic Alerts","status":"RECRUITING","sponsor":"Heart Center Research, LLC","startDate":"2021-07-08","conditions":"Heart Failure, Congestive","enrollment":80},{"nctId":"NCT04702958","phase":"","title":"TRANSFORM-HF Ancillary Mechanistic Study","status":"COMPLETED","sponsor":"Inova Health Care Services","startDate":"2020-12-10","conditions":"Heart Failure","enrollment":150},{"nctId":"NCT03354897","phase":"PHASE4","title":"Clinical Study of UMOD NKCC2 Interaction on Salt-sensitivity in Hypertension","status":"COMPLETED","sponsor":"NHS Greater Glasgow and Clyde","startDate":"2017-04-05","conditions":"Cardiovascular Diseases, Hypertension","enrollment":228},{"nctId":"NCT06039592","phase":"","title":"Study of Innovative Drug Strategies in Improving Left Ventricular Function After Mitral Repair","status":"UNKNOWN","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2022-04-01","conditions":"Congenital Mitral Insufficiency","enrollment":164},{"nctId":"NCT06039540","phase":"","title":"Study of Drug Therapy for Pediatric Heart Failure","status":"UNKNOWN","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2022-01-01","conditions":"Heart Failure Congenital","enrollment":200},{"nctId":"NCT06037434","phase":"","title":"Study of Innovative Drug Treatment Therapy for Pediatric Mitral Regurgitation","status":"UNKNOWN","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2022-04-01","conditions":"Congenital Mitral Insufficiency","enrollment":122},{"nctId":"NCT04921566","phase":"PHASE1","title":"Bioequivalence Study of Two Formulations of Torasemide Tablet 10 mg in Healthy Volunteers Under Fasting Conditions","status":"COMPLETED","sponsor":"Pharmtechnology LLC","startDate":"2021-06-05","conditions":"Bioequivalence","enrollment":26},{"nctId":"NCT03187509","phase":"PHASE4","title":"Weight-Based Torsemide Dosing in Subjects With Heart Failure","status":"COMPLETED","sponsor":"New York City Health and Hospitals Corporation","startDate":"2018-04-17","conditions":"Heart Failure","enrollment":52},{"nctId":"NCT04192110","phase":"PHASE4","title":"Association of Diuretics With Change in Extracellular Volume, Natriuretic Peptides, Symptoms, and Cardiovascular Outcomes in CKD","status":"WITHDRAWN","sponsor":"VA Office of Research and Development","startDate":"2020-08-11","conditions":"Chronic Kidney Disease","enrollment":""},{"nctId":"NCT04467931","phase":"","title":"ACEI or ARB and COVID-19 Severity and Mortality in US Veterans","status":"COMPLETED","sponsor":"University of Utah","startDate":"2020-01-19","conditions":"Hypertension, COVID","enrollment":22213},{"nctId":"NCT02288819","phase":"NA","title":"Spot Urinary Analysis to Assess Loop Diuretic Efficiency in Stable Heart Failure","status":"TERMINATED","sponsor":"Hasselt University","startDate":"2014-09","conditions":"Heart Failure","enrollment":50},{"nctId":"NCT02813551","phase":"PHASE2","title":"ToRsemide for pOstpartum HYpertension","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2016-08","conditions":"Preeclampsia","enrollment":118},{"nctId":"NCT01558674","phase":"PHASE1","title":"A Study of MK-7145 in Participants With Renal Insufficiency (Part I) and Heart Failure With Renal Insufficiency (Part II) (MK-7145-011)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-05-23","conditions":"Renal Impairment, Heart Failure","enrollment":11},{"nctId":"NCT03214874","phase":"PHASE1","title":"Within Subject Variability Study of ER Torsemide 20 mg Tablet in Healthy Subjects","status":"COMPLETED","sponsor":"Sarfez Pharmaceuticals, Inc.","startDate":"2017-06-19","conditions":"Congestive Heart Failure, Chronic Kidney Diseases","enrollment":24},{"nctId":"NCT03215875","phase":"PHASE1","title":"A Food Effect Study of 60mg ER Torsemide","status":"COMPLETED","sponsor":"Sarfez Pharmaceuticals, Inc.","startDate":"2017-10-17","conditions":"Food-drug Interaction","enrollment":28},{"nctId":"NCT00602303","phase":"NA","title":"Bioequivalency Study of Torsemide Tablets Under Fasting Conditions","status":"COMPLETED","sponsor":"Roxane Laboratories","startDate":"2003-09","conditions":"Edema","enrollment":28},{"nctId":"NCT00602615","phase":"NA","title":"Bioequivalency Study of Torsemide Tablets Under Fed Conditions","status":"COMPLETED","sponsor":"Roxane Laboratories","startDate":"2003-09","conditions":"Edema","enrollment":28},{"nctId":"NCT01942109","phase":"PHASE4","title":"The Impact of TORasemide oN hemodynAmic and Neurohormonal Stress, and carDiac remOdeling in Heart Failure","status":"UNKNOWN","sponsor":"Medical University of Warsaw","startDate":"2013-09","conditions":"Heart Failure","enrollment":100},{"nctId":"NCT02191358","phase":"","title":"YouScript IMPACT Registry","status":"COMPLETED","sponsor":"Genelex Corporation","startDate":"2014-10","conditions":"Adverse Drug Events, Adverse Drug Reactions, Drug Interaction Potentiation","enrollment":800},{"nctId":"NCT02644616","phase":"PHASE4","title":"The Safety and Efficacy of Tolvaptan for Patients With Tricuspid Regurgitation and Right Heart Failure After Left Heart Valves Replacement","status":"COMPLETED","sponsor":"Shanghai Chest Hospital","startDate":"2014-11","conditions":"Tricuspid Regurgitation, Right Heart Failure","enrollment":40},{"nctId":"NCT01457053","phase":"NA","title":"Assessment of Coronary Flow Reserve in Heart Failure Patients After Ultrafiltration Versus Diuretics","status":"TERMINATED","sponsor":"University of Cincinnati","startDate":"2011-11","conditions":"Acute Decompensated Heart Failure","enrollment":4},{"nctId":"NCT01663662","phase":"PHASE4","title":"The Use of Tolvaptan to Prevent Renal Dysfunction in High Risk Patients With Heart Failure-Pilot Study","status":"WITHDRAWN","sponsor":"University of Michigan","startDate":"2012-08","conditions":"Heart Failure","enrollment":""},{"nctId":"NCT01788254","phase":"PHASE1","title":"Open Label Study for the Functional Characterization of Drug Metabolism and Transport","status":"COMPLETED","sponsor":"Matthias Schwab","startDate":"2012-01","conditions":"Genotype-related Drug Metabolism","enrollment":144},{"nctId":"NCT00334386","phase":"PHASE4","title":"Hypertension Study: Multinational Torasemide Trial in Mild to Moderate Hypertension.","status":"COMPLETED","sponsor":"Ferrer Internacional S.A.","startDate":"2005-04","conditions":"Hypertension","enrollment":388},{"nctId":"NCT01276288","phase":"PHASE1","title":"Pharmacodynamics and Pharmacokinetics of Empagliflozin and Torasemide in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2011-01","conditions":"Diabetes Mellitus, Type 2","enrollment":23},{"nctId":"NCT01845194","phase":"PHASE1","title":"Repeated Dose Study for the Investigation of Heritability of and Genetic Influences on Drug Pharmacokinetics","status":"COMPLETED","sponsor":"Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH","startDate":"2009-12","conditions":"Drug Biotransformation, Membrane Transport","enrollment":117},{"nctId":"NCT02087332","phase":"PHASE4","title":"Investigator Initiated Randomized Open-label Comparative Study of Britomar (Prolonged Release Torasemide) and Diuver (Torasemide) to Assess Effects on Natriuresis and Central Hemodynamics.","status":"UNKNOWN","sponsor":"Society of Specialists in Heart Failure","startDate":"2014-04","conditions":"Arterial Hypertension, Chronic Heart Failure","enrollment":78},{"nctId":"NCT01549158","phase":"PHASE4","title":"Single Dose Study to Compare the Pharmacodynamics of Torasemide-PR 10 mg,Torasemide-IR 10 mg and Furosemide-IR 40 mg in Patients With Compensated Heart Failure","status":"TERMINATED","sponsor":"Ferrer Internacional S.A.","startDate":"2012-02","conditions":"Compensated Heart Failure","enrollment":8},{"nctId":"NCT00953303","phase":"PHASE2, PHASE3","title":"The Effects of Glucocorticoids on Mortality and Renal Function in Patients With Acute Decompensated Heart Failure","status":"COMPLETED","sponsor":"Hebei Medical University","startDate":"2009-01","conditions":"Heart Failure","enrollment":102},{"nctId":"NCT00653549","phase":"PHASE1","title":"Bioavailability Study of Torsemide Tablets Under Fasting Conditions","status":"COMPLETED","sponsor":"Par Pharmaceutical, Inc.","startDate":"2001-04","conditions":"To Determine Bioequivalence Under Fasting Conditions","enrollment":26},{"nctId":"NCT00409942","phase":"PHASE4","title":"Effect of a New Formulation of Torasemide (Prolonged Release)on Myocardial Fibrosis in Patients With Heart Failure.","status":"COMPLETED","sponsor":"Ferrer Internacional S.A.","startDate":"2007-03","conditions":"Congestive Heart Failure","enrollment":142},{"nctId":"NCT00295542","phase":"PHASE4","title":"Ambulatory Blood Pressure Monitoring in the Prediction of Cardiovascular Events and Effects of Chronotherapy","status":"COMPLETED","sponsor":"University of Vigo","startDate":"2000-03","conditions":"Hypertension","enrollment":3344},{"nctId":"NCT00684489","phase":"NA","title":"Renin-Guided Therapeutics in the Management of Untreated, Uncontrolled, or Complicated Hypertension","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2003-09","conditions":"Hypertension","enrollment":52},{"nctId":"NCT00654043","phase":"PHASE1","title":"Bioavailability Study of Torsemide Tablets Under Fed Conditions","status":"COMPLETED","sponsor":"Par Pharmaceutical, Inc.","startDate":"2001-04","conditions":"Healthy","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"chemblId":"CHEMBL1148"},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":395,"therapeuticAreas":["Cardiovascular"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Torasemide","genericName":"Torasemide","companyName":"Medical University of Warsaw","companyId":"medical-university-of-warsaw","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:24:52.297374+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}